# Vaxcyte Inc. (PCVX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $61.16, market value $9.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vaxcyte Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.2×**. The shares trade at 3.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.8%** (5-yr avg -7.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -28.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -48.2%**. Earnings per share fell 48.2%.

## Financial health
- **Current ratio: 7.91** (quick 7.91). Current assets cover the next year's liabilities 7.91 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vaxcyte Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Vaxcyte Inc.; the consensus is strong_buy, with an average price target of $109.00 (+78% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 90.2%** (YTD 32.6%, 3-mo 29.1%). The shares are up 90.2% over twelve months including dividends.
- **From 52-week high: -5.9%** (98.5% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.91** (volatility 46%). Beta of 0.91 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PCVX · Page: https://foliofundamentals.com/stocks/pcvx

Not investment advice.